SCP Hip Outcomes Study
Status: | Recruiting |
---|---|
Conditions: | Cardiology, Orthopedic, Orthopedic |
Therapuetic Areas: | Cardiology / Vascular Diseases, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 11/28/2018 |
Start Date: | March 27, 2018 |
End Date: | March 2025 |
Contact: | Lynsey Boyle, BS |
Email: | lynsey.boyle@zimmerbiomet.com |
Phone: | 484-467-7047 |
A Longitudinal Outcomes Study of the Subchondroplasty® Procedure in the Hip
Post-market clinical outcomes study to collect data on the short- and long-term outcomes for
subjects who are undergoing or have undergone the Subchondroplasty® (SCP®) Procedure in the
hip in a standard clinical setting. Outcomes to be assessed include medication usage, pain,
function, activity levels and patient satisfaction.
subjects who are undergoing or have undergone the Subchondroplasty® (SCP®) Procedure in the
hip in a standard clinical setting. Outcomes to be assessed include medication usage, pain,
function, activity levels and patient satisfaction.
This study is designed as a post-market, single arm, non-randomized multi-center
investigation.
Male and female subjects, at least 18 years of age, with at least one subchondral bone defect
in the form of a cyst and/or bone marrow lesion (BML), insufficiency fracture or bone defect
associated with early stage avascular osteonecrosis (AVN) in the femoral head, femoral neck
and/or acetabulum who are suitable candidates for use of AccuFill during the Subchondroplasty
Procedure are eligible for enrollment in this study.
A maximum of 15 study sites, in the United States of America, will enroll a target of 100
subjects.
Each Investigator must obtain IRB approval, or favorable opinion by an EC, prior to consent
of the first subject; no study-related procedures can occur without the approval and
oversight of a registered IRB or EC. If the study site does not have an IRB of record, a
central IRB may be utilized upon approval by Zimmer Biomet.
Demographics, medical history, hip history and use of pain medication and therapy will be
recorded at the time of subject consent. Additionally, patient reported outcomes measures
will be obtained pre-operatively. Operative details including the SCP Procedure, concomitant
surgical procedures and intraoperative safety events will be recorded at the time of surgery.
Prospective subjects will be considered enrolled in this study once their Subchondroplasty
Procedure has been performed.
Subjects will complete only the Numeric Pain Scale at 2 weeks post-operatively. Thereafter,
subjects will complete self-reported outcomes measures post-operatively at 6 weeks, 12 weeks,
6 months, 1 year and 2 years. These measures include information on pain medication and
therapy, pain levels, function, activity and subject satisfaction. A member of the study
staff will contact subjects post-operatively at 3 years, 4 years and 5 years by telephone to
verify completion of the Numeric Pain Scale and a Subject Global Satisfaction Survey.
Screening for adverse events and conversion will occur throughout the study.
Subjects will complete the study at 5 years or will be withdrawn if they undergo conversion
of the Subchondroplasty site. For the purposes of this protocol, a conversion will be defined
as total hip arthroplasty or any procedure involving removal of the AccuFill material on the
index hip.
investigation.
Male and female subjects, at least 18 years of age, with at least one subchondral bone defect
in the form of a cyst and/or bone marrow lesion (BML), insufficiency fracture or bone defect
associated with early stage avascular osteonecrosis (AVN) in the femoral head, femoral neck
and/or acetabulum who are suitable candidates for use of AccuFill during the Subchondroplasty
Procedure are eligible for enrollment in this study.
A maximum of 15 study sites, in the United States of America, will enroll a target of 100
subjects.
Each Investigator must obtain IRB approval, or favorable opinion by an EC, prior to consent
of the first subject; no study-related procedures can occur without the approval and
oversight of a registered IRB or EC. If the study site does not have an IRB of record, a
central IRB may be utilized upon approval by Zimmer Biomet.
Demographics, medical history, hip history and use of pain medication and therapy will be
recorded at the time of subject consent. Additionally, patient reported outcomes measures
will be obtained pre-operatively. Operative details including the SCP Procedure, concomitant
surgical procedures and intraoperative safety events will be recorded at the time of surgery.
Prospective subjects will be considered enrolled in this study once their Subchondroplasty
Procedure has been performed.
Subjects will complete only the Numeric Pain Scale at 2 weeks post-operatively. Thereafter,
subjects will complete self-reported outcomes measures post-operatively at 6 weeks, 12 weeks,
6 months, 1 year and 2 years. These measures include information on pain medication and
therapy, pain levels, function, activity and subject satisfaction. A member of the study
staff will contact subjects post-operatively at 3 years, 4 years and 5 years by telephone to
verify completion of the Numeric Pain Scale and a Subject Global Satisfaction Survey.
Screening for adverse events and conversion will occur throughout the study.
Subjects will complete the study at 5 years or will be withdrawn if they undergo conversion
of the Subchondroplasty site. For the purposes of this protocol, a conversion will be defined
as total hip arthroplasty or any procedure involving removal of the AccuFill material on the
index hip.
Inclusion Criteria:
- Candidates must meet ALL of the following:
1. Surgeon considers the patient appropriate for the SCP Procedure of the hip.
2. Subchondral bone defect(s) in the femoral head, femoral neck and/or acetabulum
has been confirmed via radiographic finding on MRI or x-ray.
3. Subject provides voluntary signature on the IRB approved Informed Consent Form.
4. Subject is at least 18 years of age.
5. Subject must be physically and mentally willing and able, in the Investigator's
opinion at the time of enrollment, to be compliant with the protocol and complete
outcome forms via email, telephone, in-person or by regular mail.
Exclusion Criteria:
- Candidates will be excluded if they meet ANY of the following:
1. Subject has collapse of subchondral bone.
2. Subject is pregnant at the time of surgery.
3. Subject is incarcerated.
4. Subject is involved in active litigation related to the condition being treated.
5. Subject is not comfortable with speaking, reading, and understanding questions
and providing responses in an available language for the PROs in the protocol.
We found this trial at
4
sites
Rancho Mirage, California 92270
Principal Investigator: Matthew Diltz, MD
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
Columbus, Ohio 43210
(614) 292-6446
Principal Investigator: William K Vasileff, MD
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
Click here to add this to my saved trials
Evanston, Illinois 60201
Principal Investigator: Patrick Birmingham, MD
Click here to add this to my saved trials
5875 E Riverside Blvd
Rockford, Illinois 61114
Rockford, Illinois 61114
Principal Investigator: Geoffrey Van Thiel, MD
Click here to add this to my saved trials